OBIO News, Publications Guest User OBIO News, Publications Guest User

Reviewing OBIO at RESI Boston

On September 10th, OBIO organized a cross-border networking event in Boston at the Consulate General of Canada. The event was supported by the Consulate General and law firms Fasken and Choate. Over 45 investors, strategics, as well as executives from high potential Canadian health science companies packed the Canada Room at the Consulate and resulted in numerous investor-company interactions.

Read More
Ontario Industry Updates Guest User Ontario Industry Updates Guest User

Apply for the Genomic Applications Partnership Program (GAPP)

Ontario Genomics is pleased to announce that a new round of Genome Canada’s Genomic Applications Partnership Program (GAPP) is now open (Round 18). The program provides a unique opportunity for Receptor organizations to collaborate with an ’omics researcher, and to leverage their R&D investments with public funding.

Application deadline: October 28, 2019

Click here to learn more.

Read More
Ontario Industry Updates Guest User Ontario Industry Updates Guest User

Interface Biologics Announces Sale of Surface Modification Business to Evonik

Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce the sale of its surface modification business to Evonik, a German based specialty chemical company with revenues in excess of €13 billion in 2018.

Click here for more information

Read More
Publications, OBIO News Guest User Publications, OBIO News Guest User

Reviewing 'In-Licensing from Tech Transfer Offices: Terms, Tips & Impact on Investability'

On August 21st, OBIO hosted Norton Rose Fulbright’s Anthony de Fazekas (Partner, Head of Technology & Innovation) and Vanessa Grant (Partner), Lumira Ventures’ Jacki Jenuth (Partner), and University of Toronto’s Karen Temple (Commercialization Manager) who discussed practical considerations for licensing health science technologies from tech transfer offices, and how these agreements can impact a company’s future investability.

Read More